Misoprostol in addition to routine treatment of postpartum hemorrhage: a hospital-based randomized-controlled trial in Karachi, Pakistan

Nadeem F Zuberi, Jill Durocher, Rozina Sikander, Neelofur Baber, Jennifer Blum, Gijs Walraven, Nadeem F Zuberi, Jill Durocher, Rozina Sikander, Neelofur Baber, Jennifer Blum, Gijs Walraven

Abstract

Background: Postpartum hemorrhage (PPH) remains a major killer of women worldwide. Standard uterotonic treatments used to control postpartum bleeding do not always work and are not always available. Misoprostol's potential as a treatment option for PPH is increasingly known, but its use remains ad hoc and available evidence does not support the safety or efficacy of one particular regimen. This study aimed to determine the adjunct benefit of misoprostol when combined with standard oxytocics for PPH treatment.

Methods: A randomized controlled trial was conducted in four Karachi hospitals from December 2005 - April 2007 to assess the benefit of a 600 mcg dose of misoprostol given sublingually in addition to standard oxytocics for postpartum hemorrhage treatment. Consenting women had their blood loss measured after normal vaginal delivery and were enrolled in the study after losing more than 500 ml of blood. Women were randomly assigned to receive either 600 mcg sublingual misoprostol or matching placebo in addition to standard PPH treatment with injectable oxytocics. Both women and providers were blinded to the treatment assignment. Blood loss was collected until active bleeding stopped and for a minimum of one hour after PPH diagnosis. Total blood loss, hemoglobin measures, and treatment outcomes were recorded for all participants.

Results: Due to a much lower rate of PPH than expected (1.2%), only sixty-one patients were diagnosed and treated for their PPH in this study, and we were therefore unable to measure statistical significance in any of the primary endpoints. The addition of 600 mcg sublingual misoprostol to standard PPH treatments does, however, suggest a trend in reduced postpartum blood loss, a smaller drop in postpartum hemoglobin, and need for fewer additional interventions. Women who bled less overall had a significantly smaller drop in hemoglobin and received fewer additional interventions. There were no hysterectomies or maternal deaths among study participants. The rate of transient shivering and fever was significantly higher among women receiving misoprostol

Conclusion: A 600 mcg dose of misoprostol given sublingually shows promise as an adjunct treatment for PPH and its use should continue to be explored for its life-saving potential in the care of women experiencing PPH.

Trial registration: Clinical trials.gov, Registry No. NCT00116480.

References

    1. Derman RJ, Kodkany BS, Goudar SS, Geller SE, Naik VA, Bellad MB, Patted SS, Patel A, Edlavitch SA, Hartwell T, Chakraborty H, Moss N. Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial. Lancet. 2006;368:1248–1253. doi: 10.1016/S0140-6736(06)69522-6.
    1. Alfirevic A, Blum J, Walraven G, Weeks A, Winikoff B. Prevention of postpartum hemorrhage with misoprostol. Int J Gynecol Obstet. 2007;99:198–201. doi: 10.1016/j.ijgo.2007.09.012.
    1. Lokugamage AU, Sullivan KR, Niculescu I, Tigere P, Onyangunga F, El Refaey H, Moodley J, Rodeck CH. A randomized study comparing rectally administered misoprostol versus Syntometrine combined with an oxytocin infusion for the cessation of primary post partum hemorrhage. Acta Obstet Gynecol Scand. 2001;80:835–839. doi: 10.1034/j.1600-0412.2001.080009835.x.
    1. Hofmeyr GJ, Ferreira S, Nikodem VC, Mangesi L, Singata M, Jafta Z, Maholwana B, Mlokoti Z, Walraven G, Gülmezoglu AM. Misoprostol for treating postpartum hemorrhage: a randomized controlled trial. BJOG. 2004;111:1014–1019. doi: 10.1111/j.1471-0528.2004.00217.x.
    1. Walraven G, Dampha Y, Bittaye B, Sowe M, Hofmeyr J. Misoprostol in the treatment of postpartum haemorrhage in addition to routine management: a placebo randomized controlled trial. BJOG. 2004;111:1014–1017. doi: 10.1111/j.1471-0528.2004.00217.x.
    1. Hofmeyr GJ, Walraven G, Gülmezoglu AM, Alfirevis Z, Villar J. Misoprostol to treat postpartum hemorrhage: a systematic review. BJOG. 2005;112:547–553. doi: 10.1111/j.1471-0528.2004.00512.x.
    1. Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database of Systematic Reviews. 2007;1:CD 003249.
    1. O'Brien P, El-Refaey H, Gordon A, Geary M, Rodeck CH. Rectally administered misoprostol for the treatment of postpartum hemorrhage unresponsive to oxytocin and ergometrine: a descriptive study. Obstet Gynecol. 1998;92:212–214. doi: 10.1016/S0029-7844(98)00161-6.
    1. Ozan H, Bilgin T, Ozsarac N, Ozerkan RK, Cengiz C. Misoprostol in uterine atony: a report of 2 cases. Clin Exp Obstet Gynecol. 2000;27:221–222.
    1. Abdel-aleem H, El-Nashar I, Abdel-Aleem A. Management of severe postpartum hemorrhage with misoprostol. Int J Gynecol Obstet. 2001;72:75–76. doi: 10.1016/S0020-7292(00)00321-0.
    1. Shojai R, Debriere R, Dhifallah S, Courbiere B, Ortega D, d'Ercole C, Boubli L. [Rectal misoprostol for postpartum hemorrhage] Gynecol Obstet Fertil. 2004;32:703–707. doi: 10.1016/j.gyobfe.2004.05.015. French.
    1. Shojai R, Piechon L, d'Ercole C, Boubli L, Ponties JE. [Rectal administration of misoprostol for delivery induced hemorrhage. Preliminary study] J Gynecol Obstet Biol Reprod (Paris) [Article in French] . 2001;30:572–575.
    1. Adekanmi OA, Purmessur S, Edwards G, Barrington JW. Intrauterine misoprostol for the treatment of severe recurrent atonic secondary postpartum haemorrhage. BJOG. 2001;108:541–545. doi: 10.1016/S0306-5456(00)00110-8.
    1. Oboro VO, Tabowei TO, Bosah JO. Intrauterine misoprostol for refractory postpartum hemorrhage. Int J Gynecol Obstet. 2003;80:67–68. doi: 10.1016/S0020-7292(02)00301-6.
    1. Prata N, Mbaruku G, Campbell M, Potts M, Vahidnia F. Controlling postpartum hemorrhage after home births in Tanzania. Int J Gynaecol Obstet. 2005;90:51–55. doi: 10.1016/j.ijgo.2005.03.007.
    1. Blum J, Alfirevic Z, Walraven G, Weeks A, Winikoff B. Treatment of postpartum hemorrhage with misoprostol. Int J Gynaecol Obstet. 2007:202–205. doi: 10.1016/j.ijgo.2007.09.013.
    1. Bhutta S, Jafarey SN, Midhet F. Safe motherhood. A situation analysis and recommendations for evidence-based approaches. In: Bhutta ZA, editor. Maternal and child health in Pakistan Challenges and opportunities. Karachi: Oxford University Press; 2004. pp. 1–18.
    1. Hill K, Thomas K, AbouZahr C, Walker N, Say L, Inoue M, Suzuki E, Maternal Mortality Working Group Estimates of maternal mortality worldwide between 1990 and 2005: an assessment of available data. Lancet. 2007;370:1311–1319. doi: 10.1016/S0140-6736(07)61572-4.
    1. Duthie SJ, Ven D, Yung GL, Guang DZ, Chan SY, Ma HK. Discrepancy between laboratory determination and visual estimation of blood loss during normal delivery. Eur J Obstet Gynecol Reprod Biol. 1991;38:119–124. doi: 10.1016/0028-2243(91)90188-Q.
    1. Razvi K, Chua S, Arulkumaran S, Ratnam SS. A comparison between visual estimation and laboratory determination of blood loss during the third stage of labour. Aust N Z J Obstet Gynaecol. 1996;36:152–154. doi: 10.1111/j.1479-828X.1996.tb03273.x.
    1. Prasertcharoensuk W, Swadpanich U, Lumbiganon P. Accuracy of the blood loss estimation in the third stage of labor. Int J Gynaecol Obstet. 2000;71:69–70. doi: 10.1016/S0020-7292(00)00294-0.
    1. Patel A, Goudar SS, Geller SE, Kodkany BS, Edlavitch SA, Wagh K, Patted SS, Naik VA, Moss N, Derman RJ. Drape estimation vs. visual assessment for estimating postpartum hemorrhage. Int J Gynaecol Obstet. 2006;93:220–224. doi: 10.1016/j.ijgo.2006.02.014.
    1. Prendiville WJ, Elbourne D, McDonald S. Active versus expectant management in the third stage of labor. Cochrane Database Syst Rev. 2000;2:CD000007.
    1. Soriano D, Dulitzki M, Schiff E, Barkai G, Mashiach S, Seidman DS. A prospective cohort study of oxytocin plus ergometrine compared with oxytocin alone for prevention of postpartum haemorrhage. Br J Obstet Gynaecol. 1996;103:1068–1073.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa